UK Life Sciences Vision sets 10-year strategy for sector to solve some of the biggest healthcare problems of our generation, including cancer and dementia.
- UK Life Sciences Vision sets 10-year strategy for sector to build on successes of COVID-19 response and accelerate delivery of innovations to patients- mission-led approach to solve some of the biggest healthcare problems of our generation, including cancer and demential- aunch of Life Sciences Investment Programme brings total amount of funding available to UK’s most promising life sciences companies to £1 billion
The remarkable…
Tokyo, Japan, and Cambridge, UK, 6 July 2021 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in GPCR-focused structure-based drug design and development, and InveniAI® LLC (“InveniAI,” Guilford, CT, USA), a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, announced today the initiation of a new R&D collaboration.
The objective of the collaboration is to identify new therapeutic product concepts for immune diseases where an AI and ML based approach can…
We have taken home the most coveted prize at the inaugural eprivateclient Excellence Awards.
An online black tie gala ceremony was held on 24 June to announce the awards, designed to recognise the outstanding achievements of eprivateclient’s top-ranked firms. This included firms from across the UK working in offshore legal, tax, fiduciary and advisory professional services over the last 12 months. Overall, 66 firms entered the 11 categories, with 27 contestants shortlisted.
eprivateclient said the five awards across the legal sector were the most hotly contested, with the most popular award…
We have officially launched LitiGate's AI-driven litigation platform across our network of contentious teams.
The firm has moved from a test phase of the tool on a select number of cases, to a rollout across the wider community of contentious practices involving its application to many of the most significant pieces of litigation or arbitration.
We chose LitiGate as our go-to litigation lifecycle platform to support clients with contentious matters, following our work with the platform's developers during the testing phase.
The firm supported LitiGate's ground-breaking…
Brussels South Charleroi BioPark (BSCB) recently announced it has launched a Cell and Gene Therapy Accelerator program to de-risk early stage research and create the advanced therapy companies of the future. Open to academic, industry or independent researchers across Europe, the program consists of an intensive bootcamp, workshops and coaching, plus access to Université libre de Bruxelles (ULB) Open BioLab and state-of-the-art technology platforms.
Cambridge, UK: 30 June 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge exists to support growing Life Science businesses on their journey, including facilitating their business networking. BiotechBikers is a fast growing, informal global networking group in the Life Sciences space bringing together those with a social interest in cycling and biotech.
Dr Mark Farmery, founder of BiotechBikers commented, “Authentic and robust personal relationships are pivotal in successful collaboration and deal making. By engaging people around a shared passion…
AMSBIO have supplied custom lentivectors to Francesco Pampaloni and his team at the Buchmann Institute for Molecular Life Sciences (BMLS) in Frankfurt, Germany allowing them to visualize cell nuclei and F-actin cytoskeleton in their organoids.Organoids are morphologically heterogeneous 3-dimensional cell culture systems that provide an ideal model for understanding the principles of collective cell behavior in mammalian organs during development, homeostasis, regeneration, and pathogenesis. To investigate the underlying cell organization principles of organoids, BMLS researchers imaged…
Oxford, UK, 29 June 2021: PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert with respect to Spectral MD’s listing on London’s AIM on June 22nd.Adrian Dawkes, Managing Director at PharmaVentures, said: “Through our expert knowledge across the medical device sector, and in particular the wound care market, we were pleased to be able to provide an independent expert assessment of Spectral’s DeepView® Wound Imaging System with respect to their Initial Public Offering (IPO) on AIM.”Fintan Walton, Chief Executive of PharmaVentures, said: “…